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Tobacco smoking and tuberculosis treatment outcomes: a prospective 
cohort study in Georgia
Medea Gegia,a Matthew J Magee,b Russell R Kempker,c Iagor Kalandadze,d Tsira Chakhaia,a Jonathan E Golube & 
Henry M Blumbergc
Introduction
Both tobacco smoking and tuberculosis are major global 
public health problems. Globally, nearly 6 million people died 
from tobacco use in 2011 and tobacco use is estimated to be 
responsible for 16% of deaths among men and 7% of deaths 
among women each year.1,2 In 2012, there were an estimated 
8.6 million new tuberculosis cases and 1.3 million tubercu-
losis-related deaths worldwide.2 Smoking is common in the 
22 countries categorized by the World Health Organization 
(WHO) as high-burden countries for tuberculosis – which 
together account for more than 80% of all tuberculosis cases. 
The burden of smoking among patients with tuberculosis is 
poorly defined in most countries.2
An understanding of the epidemiological relationship 
between smoking and tuberculosis is important because 
both smoking and tuberculosis cause extensive morbidity 
and mortality worldwide. Compared with those who have 
never smoked, it is estimated that people who smoke have 
approximately twice the risk of both Mycobacterium tubercu-
losis infection3 and active tuberculosis.4 However, data on the 
impact of smoking on treatment outcomes among patients 
with active tuberculosis are limited.5
Georgia has a high incidence of tuberculosis, a high 
incidence of multidrug-resistant (MDR) tuberculosis and a 
high prevalence of smoking.6,7 In 2012, for example, there 
were 116 cases of tuberculosis per 100 000 people and MDR 
tuberculosis accounted for 9.2% of the new cases and 31.0% of 
the retreatment cases.6 In 2010, a national survey indicated that 
about 52.8% of Georgian men – including 64.0% of those aged 
30–49 years – and 6.1% of Georgian women were smokers.7 
The main objectives of this study were to estimate the preva-
lence of smoking and the impact of smoking on tuberculosis 
treatment outcomes among patients with tuberculosis in the 
Georgian capital of Tbilisi.
Methods
Design and study population
A prospective cohort study was conducted between May 2011 
and November 2013 among people attending the National 
Centre for Tuberculosis and Lung Diseases, or one of its af-
filiated outpatient clinics, in Tbilisi, Georgia. To be eligible 
for enrolment, a patient had to be aged at least 18 years, have 
provided a sputum specimen that had been found either 
smear-positive for acid-fast bacilli or culture-positive for My-
cobacterium tuberculosis and have started directly-observed, 
standard tuberculosis therapy according to WHO guidelines8 
within the previous two months. Eligible patients were en-
rolled between May 2011 and February 2012. In November 
2013, details of the participants’ treatment outcomes were 
collected from the database of patient records maintained 
by the National Centre for Tuberculosis and Lung Diseases.
At the time of study enrolment, after the patients had pro-
vided written informed consent, our research team conducted 
face-to-face interviews of eligible inpatients and outpatients. 
Although most of the data we used were collected using a stan-
dardized questionnaire adapted from the one employed in the 
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global adult tobacco survey,9 additional 
covariates of interest were collected from 
the National Centre for Tuberculosis and 
Lung Diseases database. Self-reported 
information on age, alcohol use, socio-
economic indicators, prison history, 
human immunodeficiency virus (HIV) 
status, exposure to a person with MDR 
tuberculosis and tuberculosis symptoms 
– i.e. cough with and without sputum 
– were recorded on the questionnaire. 
Previous tuberculosis treatment, results 
from the examination of a baseline 
sputum smear and current tuberculosis 
treatment regimen were obtained from 
the National Centre for Tuberculosis and 
Lung Diseases database.
Study definitions
History of smoking was used as the primary 
exposure variable. Patients were first asked 
if they currently smoked on a daily basis, 
less than daily, or not at all. Those who re-
ported that they currently smoked – either 
daily or less than daily – were categorized 
as current smokers in the primary analyses. 
The remaining patients were then asked 
if they had smoked in the past on a daily 
or less than daily basis and those giving a 
positive response were categorized as past 
smokers in the primary analyses. Patients 
who said that they had never smoked were 
always categorized as never smokers.
In our secondary analyses, we used 
other measures of tobacco use. Patients 
who currently smoked on a daily basis 
and patients who currently smoked on 
a less than daily basis were separately 
compared with past and never smokers. 
Patients also reported smokeless tobacco 
use and frequency of household second-
hand exposure to tobacco smoke. To 
account for possible misclassification of 
those patients who had stopped smok-
ing once they developed tuberculosis 
symptoms,10,11 we also used modified 
definitions for smoking status. For ex-
ample, we put patients who had ceased 
smoking in the two or four months 
before enrolment in separate categories 
and reclassified all such patients as cur-
rent smokers instead of past smokers.12,13
The outcome of each participant’s 
most recent treatment for tuberculosis 
was used as the primary study outcome. 
Treatment outcomes were categorized 
according to WHO definitions.6 A 
patient who was cured or completed 
treatment was defined as having a 
favourable outcome whereas a patient 
who defaulted, failed treatment or died 
was defined as having a poor outcome.
Laboratory studies were performed 
at the Georgia National Tuberculosis 
Reference Laboratory. Since 2005, the 
quality of the services provided by this 
laboratory has been assessed annually by 
the WHO’s Supranational Tuberculosis 
Reference Laboratory in Antwerp, Bel-
gium.14 A standard semiquantitative scale 
was used to classify the number of acid-
fast bacilli present in sputum smears.15 
Sputum samples were tested for M. tuber-
culosis by culture on Lowenstein–Jensen 
solid medium and using BACTEC MGIT 
960 mycobacterial detection system (BD, 
Franklin Lakes, United States of Ameri-
ca).14 Isolated samples of M. tuberculosis 
were tested for their sensitivity to first-
line anti-tuberculosis drugs using either 
the absolute concentration method or 
the BACTEC MGIT 960 mycobacterial 
detection system but their sensitivity to 
second-line drugs was investigated using 
proportion methods.14
Data analyses
Study data were entered into a REDCap16 
electronic database and analysed using 
SAS 9.3 (SAS Institute, Cary, USA). Bi-
variate associations were analysed using 
χ2 tests for categorical variables and the 
Wilcoxon rank sum or Kruskal–Wallis 
tests for continuous variables. A two-
sided P-value of less than 0.05 was con-
sidered statistically significant. Binomial 
regression models were used to estimate 
risk ratios (RR) and 95% confidence 
intervals (CI) for a poor tuberculosis 
treatment outcome. Potential confound-
ers – based on significant bivariate asso-
ciations with the primary exposure and 
outcome, previous literature or directed 
acyclic graph theory17 – were included 
in the regression models. We used the 
primary multivariable model to estimate 
the effect of current smoking status on 
risk of poor tuberculosis outcome. For 
our secondary models we used alter-
native definitions of current smoking 
status but included the same covariates 
as in the primary model. To assess the 
distribution of missing outcome data, we 
compared the sociodemographic, tuber-
culosis and smoking characteristics of 
the patients with known treatment out-
comes with those of the other patients. 
The study was reviewed and approved 
by the institutional review boards of the 
Georgia National Centre for Tuberculo-
sis and Lung Diseases (Tbilisi, Georgia), 
Emory University (Atlanta, USA) and 
the Johns Hopkins Bloomberg School of 
Public Health (Baltimore, USA).
Results
Overall, 591 (64.4%) of 917 eligible pa-
tients with tuberculosis were invited to 
participate in our study and all agreed 
to be enrolled. Of the participants, 457 
(77.3%) were male. The median age was 
36 years (interquartile range, IQR: 26–50 
years), their median monthly income 
was 118 United States dollars (US$) 
(IQR: US$ 59–294) and 465 (78.7%) 
of them had been educated to at least 
high school level. In November 2013, 
information on tuberculosis treatment 
outcome was available for 524 (88.7%) 
of the participants.
Smoking characteristics
Of the participants, 271 (45.9%) were 
current smokers and 188 (31.8%) were 
past smokers (Table 1). Most of the 
current and past smokers were male. 
Current smokers were older, with fewer 
years of education and lower income 
compared to never smokers (Table 1). 
Previous tuberculosis treatment, cough 
with sputum and exposure to a case of 
MDR tuberculosis were more frequently 
reported by current smokers than never 
smokers (Table 1). Compared with the 
never smokers, past smokers were 
significantly less likely to have MDR 
tuberculosis (Table 1).
Treatment outcomes
We were unable to determine the final 
treatment outcomes of 67 participants 
because of missing data (34) or because, 
at the end of our study, the participants 
remained on second-line therapy against 
MDR tuberculosis (33). We collected 
information on the final treatment out-
comes of the remaining 524 participants. 
Of these participants, 128 (24.4%) had a 
poor outcome – 99 defaulted, 11 failed 
treatment and 18 died (Table 2). In 
terms of their demographic character-
istics, baseline smear status and smok-
ing characteristics, the 524 participants 
with known treatment outcomes did 
not appear to be significantly different 
to the  67 other participants.
In our unadjusted analyses, the 
risk of poor treatment outcomes was 
higher among current smokers (RR: 
1.91; 95% CI: 1.25–2.94), males (RR: 
1.74; 95% CI: 1.12–2.71), those with a 
history of imprisonment (RR: 1.46; 95% 
CI: 1.05–2.03), previous tuberculosis 
treatment (RR: 1.94; 95% CI: 1.45–2.61), 
sputum-smear-positive at the baseline 
check (RR: 2.33; 95% CI: 1.61–3.37) or 
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Table 1. Baseline characteristics of adults with active tuberculosis, Georgia, 2011–2012
Characteristic No. (%)a P
Never smokers (n = 132) Past smokers (n = 188) Current smokers (n = 271)
Sex
Female 89 (67.4) 26 (13.8) 19 (7.0) < 0.01
Male 43 (32.6) 162 (86.2) 252 (93.0)
Age (years)
18–24 47 (35.6) 39 (20.7) 30 (11.1) < 0.01
25–34 38 (28.8) 42 (22.3) 73 (26.9)
35–54 24 (18.2) 80 (42.6) 128 (47.2)
≥ 55 23 (17.4) 27 (14.4) 40 (14.8)
Education (years)
≤ 9 29 (22.0) 33 (17.5) 64 (23.6) < 0.01
10 33 (25.0) 77 (41.0) 118 (43.5)
≥ 11 70 (53.0) 78 (41.5) 89 (32.8)
Monthly income (US$)
≤ 65 25 (18.9) 59 (31.4) 95 (35.1) 0.02
66–200 49 (37.1) 50 (26.6) 86 (31.7)
≥ 201 48 (36.4) 59 (31.4) 72 (26.6)
Unknown 10 (7.6) 20 (10.6) 18 (6.6)
Internally displaced
No 123 (93.2) 173 (92.0) 250 (92.3) 0.92
Yes 9 (6.8) 15 (8.0) 21 (7.7)
Prison history
No 127 (96.2) 163 (86.7) 181 (66.8) < 0.01
Yes 5 (3.8) 25 (13.3) 90 (33.2)
Frequency of alcohol use (days/
week)
0 74 (56.1) 50 (26.6) 51 (18.8) < 0.01
< 1 45 (34.1) 61 (32.5) 75 (27.7)
1–2 9 (6.8) 42 (22.3) 66 (24.4)
≥ 3 2 (1.5) 26 (13.8) 76 (28.0)
Unknown 2 (1.5) 9 (4.8) 3 (1.1)
Self-reported HIV status
Negative 117 (88.6) 168 (89.4) 243 (89.7) 0.86
Positive 2 (1.5) 3 (1.6) 3 (1.1)
Unknown 13 (9.9) 17 (9.0) 25 (9.2)
Smokeless tobacco use
No 95 (72.0) 147 (78.2) 195 (72.0) 0.39
Yes 1 (0.7) 4 (2.1) 5 (1.8)
Unknown 36 (27.3) 37 (19.7) 71 (26.2)
Second-hand exposure to smoke in 
household
Never 49 (37.1) 97 (51.6) 108 (39.9) < 0.01
Less than daily 20 (15.1) 17 (9.0) 22 (8.1)
Daily 62 (47.0) 68 (36.2) 118 (43.5)
Unknown 1 (0.8) 6 (3.2) 23 (8.5)
Previous tuberculosis treatment
No 108 (81.8) 147 (78.2) 181 (66.8) < 0.01
Yes 24 (18.2) 41 (21.8) 90 (33.2)
Result of baseline sputum 
examination
Negative for AFB 65 (49.2) 85 (45.2) 102 (37.6) 0.06
Positive for AFB 67 (50.8) 103 (54.8) 169 (62.4)
Self-reported cough
No 31 (23.5) 45 (23.9) 53 (19.6) 0.03
(continues. . .)
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MDR tuberculosis (RR: 4.53; 95% CI: 
3.30–6.21) (Table 3). In the primary 
multivariable analysis, being a current 
smoker (RR: 1.70; 95% CI: 1.00–2.90) 
and receiving treatment for MDR tu-
berculosis (RR: 3.12; 95% CI: 2.30–4.22) 
remained significantly associated with a 
poor outcome (Table 3). We did not de-
tect any one-way statistical interactions 
between smoking status and any of the 
other covariates that we included in the 
adjusted model.
Compared with never smokers, pa-
tients with tuberculosis who had ceased 
smoking within the two months before 
enrolment had an increased – but not 
significantly increased – adjusted risk 
of a poor treatment outcome (adjusted 
relative risk, aRR: 1.44; Table 4). In 
models 3 and 4, we considered patients 
who had ceased smoking in the two 
and four months before enrolment as 
current smokers, respectively, and this 
reduced the strength of the apparent as-
sociation between current smoking and 
a poor treatment outcome – to give ad-
justed relative risks of 1.67 and 1.64, re-
spectively (Table 4). Patients who, when 
enrolled, had ceased smoking for more 
than two months had a similar risk of a 
poor treatment outcome to those who 
had never smoked (RR: 1.01; Table 4). 
There were no significant associations 
between poor tuberculosis treatment 
outcomes and smokeless tobacco use 
or household second-hand exposure to 
tobacco smoke.
Discussion
There is a high prevalence of smok-
ing among patients with tuberculosis 
in Georgia and, among such patients, 
smoking significantly increases the risk 
of a poor treatment outcome. After 
adjusting for other individual charac-
teristics that are potentially related to 
both smoking and tuberculosis treat-
ment outcome, we found that the risk of 
a poor tuberculosis treatment outcome 
was 70% greater in current smokers 
compared to never smokers. Patients 
being treated for MDR tuberculosis had 
a 3-fold greater risk of a poor outcome 
compared to patients being treated for 
other forms of tuberculosis. We also 
found that patients who had recently 
stopped smoking had a lower risk of a 
poor tuberculosis outcome than current 
smokers.
As the government in Georgia 
prepares for new national policy on to-
bacco control, the findings of our study 
are particularly timely and relevant. In 
Georgia, it is currently illegal to smoke 
in medical facilities18 but it has been 
difficult to enforce this legislation. Ad-
ditional policies are needed to eliminate 
or at least reduce tobacco use in health-
Characteristic No. (%)a P
Never smokers (n = 132) Past smokers (n = 188) Current smokers (n = 271)
Yes 101 (76.5) 139 (73.9) 218 (80.4)
Unknown 0 (0.0) 4 (2.1) 0 (0.0)
Self-reported cough with sputum
No 28 (21.2) 12 (6.4) 21 (7.7) < 0.01
Yes 71 (53.8) 121 (64.4) 191 (70.5)
Unknown 33 (25.0) 55 (29.3) 59 (21.8)
Self-reported exposure to case of 
MDR tuberculosis
No 97 (73.5) 139 (73.9) 158 (58.3) < 0.01
Yes 35 (26.5) 44 (23.4) 111 (41.0)
Unknown 0 (0.0) 5 (2.7) 2 (0.7)
Type of tuberculosis
Drug-susceptible 78 (59.1) 131 (69.7) 170 (62.7) < 0.01
MDR 52 (39.4) 46 (24.5) 95 (35.1)
Unknown 2 (1.5) 11 (5.9) 6 (2.2)
Median values
Age, years (IQR) 29.0 (22.0–43.0) 36.0 (25.0–51.0) 39.0 (29.0–50.0) < 0.01
Education, years (IQR) 11.0 (10.0–11.0) 10.0 (10.0–11.0) 10.0 (10.0–11.0) < 0.01
Monthly income, US$ (IQR) 176.5 (88.2–294.1) 117.6 (58.8–294.1) 117.6 (41.2–235.3) < 0.01
AFB: acid-fast bacilli; HIV: human immunodeficiency virus; IQR: interquartile range; MDR: multidrug-resistant; US$: United States dollars.
a  Unless indicated otherwise.
Table 2. Smoking status and treatment outcomes among adults with tuberculosis, 
Georgia, 2011–2012
Treatment outcomea No. (%)
Never smokers 
(n = 122)
Past smokers 
(n = 159)
Current smokers 
(n = 243)
Favourable 101 (82.8) 132 (83.0) 163 (67.1)
Cured 42 (34.4) 69 (43.4) 81 (33.3)
Completed treatment 59 (48.4) 63 (39.6) 82 (33.7)
Poor 21 (17.2) 27 (17.0) 80 (32.9)
Defaulted treatment 16 (13.1) 22 (13.8) 61 (25.1)
Failed treatment 1 (0.8) 3 (1.9) 7 (2.9)
Died 4 (3.3) 2 (1.3) 12 (4.9)
a  As defined by the World Health Organization6 and recorded six months after the initiation of treatment.
Note: Inconsistencies arise in some values due to rounding.
(. . .continued)
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Table 3. Association between baseline patient characteristics and risk of poor tuberculosis treatment outcomes, Georgia, 2011–2012
Characteristic No. of patients with poor/known 
outcome (%)
Risk ratio (95% CI)a
Crude Adjustedb
Sex
Female 19/122 (15.6) 1.00 1.00
Male 109/402 (27.1) 1.74 (1.12–2.71) 1.12 (0.67–1.86)
Age (years)
18–24 22/109 (20.2) 1.00 1.00
25–34 32/134 (23.9) 1.18 (0.73–1.91) 1.04 (0.68–1.58)
35–54 49/199 (24.6) 1.22 (0.78–1.90) 0.86 (0.60–1.25)
≥ 55 25/82 (30.5) 1.51 (0.92–2.48) 1.17 (0.83–1.64)
Education (years)
≤ 9 32/114 (28.1) 1.00 –
10 50/197 (25.4) 0.90 (0.62–1.32) –
≥ 11 46/213 (21.6) 0.77 (0.52–1.14) –
Monthly income (US$)
≤ 65 36/161 (22.4) 1.00 1.00 (0.99–1.00)c
66–200 53/165 (32.1) 1.44 (1.00–2.07) –
≥ 201 29/156 (18.6) 0.83 (0.54–1.29) –
Unknown 10/42 (23.8) – –
Internally displaced
No 120/488 (24.6) 1.00 –
Yes 8/36 (22.2) 0.90 (0.48–1.70) –
Prison history –
No 94/420 (22.4) 1.00 1.00
Yes 34/104 (32.7) 1.46 (1.05–2.03) 1.12 (0.82–1.53)
Frequency of alcohol use (days/week)
0 29/158 (18.4) 1.00 1.00
< 1 49/153 (32.0) 1.74 (1.17–2.61) 1.02 (0.72–1.44)d
1–2 28/106 (26.4) 1.44 (0.91–2.27) –
≥ 3 20/94 (21.3) 1.16 (0.70–1.93) –
Unknown 2/13 (15.4) – –
Previous tuberculosis treatment
No 78/394 (19.8) 1.00 1.00
Yes 50/130 (38.5) 1.94 (1.45–2.61) 1.22 (0.94–1.58)
Result of baseline sputum examination
Negative for AFB 30/218 (13.8) 1.00 1.00
Positive for AFB 98/306 (32.0) 2.33 (1.61–3.37) 1.37 (0.99–1.90)
Self-reported cough
No 25/120 (20.8) 1.00 –
Yes 103/401 (25.7) 1.23 (0.84–1.81) –
Unknown 0/3 (0.0) – –
Self-reported cough with sputum
No 11/54 (20.4) 1.00 –
Yes 84/334 (25.1) 1.23 (0.71–2.16) –
Unknown 33/136 (24.3) – –
Self-reported exposure to case of MDR 
tuberculosis
No 83/350 (23.7) 1.00 –
Yes 44/167 (26.3) 1.11 (0.81–1.52) –
Unknown 1/7 (14.3) – –
Type of tuberculosis
Drug-susceptible 43/364 (11.8) 1.00 1.00
MDR 85/159 (53.5) 4.53 (3.30–6.21) 3.12 (2.30–4.22)
Unknown 0/1 (0.0) – –
Self-reported HIV status
(continues. . .)
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care settings in general and tuberculosis 
clinics in particular. Future policies on 
tobacco use in the country should pro-
mote smoking cessation programmes for 
patients with tuberculosis.
Globally, more than 20% of people 
older than 15 years smoke tobacco, 
according to WHO data from 2014.19 
However, the prevalence of smoking 
among people with tuberculosis is often 
well above 20%. For example, a South 
African study observed that 56% of 
patients with active tuberculosis were 
current smokers.20 Similarly, 54.6% of 
Chinese patients with tuberculosis were 
smokers.13 In our study, 59.9% of the 
tuberculosis patients were either current 
smokers or individuals who had ceased 
smoking no more than two months ear-
lier. Because smoking induces coughing 
and other symptoms consistent with 
tuberculosis, there may be longer delays 
in the diagnosis of tuberculosis among 
smokers than among non-smokers. For 
example, another study in Georgia re-
ported a greater likelihood of prolonged 
delay (more than 23 days) in active 
tuberculosis diagnosis in smokers com-
pared to never smokers (adjusted odds 
ratio, aOR: 3.03; 95% CI: 1.24–7.40).21
At the time of our study, few data 
had been published on the relationship 
between smoking and treatment out-
comes among patients with tuberculo-
sis.22,23 Georgian patients whose sputum 
samples had been found culture-positive 
for MDR tuberculosis were less likely 
to become culture-negative after treat-
ment if they currently smoked, (adjusted 
hazard ratio: 0.82; 95% CI: 0.71–0.95).24 
Other studies have shown that smok-
ing is associated with increased risk of 
Characteristic No. of patients with poor/known 
outcome (%)
Risk ratio (95% CI)a
Crude Adjustedb
Negative 118/464 (25.4) 1.00 1.00
Positive 1/8 (12.5) 0.49 (0.08–3.10) –
Unknown 9/52 (17.3) – –
Model 1 – smoking status
Never smoker 21/122 (17.2) 1.00 1.00
Past smoker 27/159 (17.0) 0.99 (0.59–1.66) 1.24 (0.71–2.17)
Current smoker 80/243 (32.9) 1.91 (1.25–2.94) 1.70 (1.00–2.90)
Model 2 – smoking status
Never smoker 21/122 (17.2) 1.00 –
Past smoker 9/86 (10.5) 0.61 (0.29–1.26) –
Ceased smoking in previous two months 18/73 (24.7) 1.43 (0.82–2.50) –
Current smoker 80/243 (32.9) 1.91 (1.25–2.94) –
Model 3 – smoking status
Never smoker 21/122 (17.2) 1.00 –
Past smoker 9/86 (10.5) 0.61 (0.29–1.26) –
Current smokere 98/316 (31.0) 1.80 (1.18–2.75) –
Model 4 – smoking status
Never smoker 21/122 (17.2) 1.00 –
Past smoker 6/70 (8.6) 0.50 (0.21–1.17) –
Current smokerf 101/332 (30.4) 1.77 (1.16–2.69) –
Current smoking frequency
Zero 48/280 (17.1) 1.00 –
Less than daily 3/13 (23.1) 1.35 (0.48–3.75) –
Daily 77/231 (33.3) 1.94 (1.42–2.67) –
Smokeless tobacco use
No 90/385 (23.4) 1.00 –
Yes 2/9 (22.2) 0.95 (0.28–3.27) –
Unknown 36/130 (27.7) – –
Second-hand exposure to smoke in 
household
Never 52/224 (23.2) 1.00 –
Less than daily 23/52 (44.2) 1.91 (1.29–2.81) –
Daily 46/221 (20.8) 0.90 (0.63–1.27) –
Unknown 7/27 (25.9) –
AFB: acid-fast bacilli; CI: confidence interval; HIV: human immunodeficiency virus; MDR: multidrug-resistant; US$: United States dollars.
a  For a poor treatment outcome – i.e. death or treatment default or failure – recorded six months after the initiation treatment.
b  Each ratio was adjusted for all of the other variables for which adjusted odds ratios are given in the table.
c  Per US$ 10 increase in monthly income.
d  Value for any alcohol use versus none.
e  Including patients who ceased smoking before two months of enrolment.
f  Including patients who ceased smoking before four months of enrolment.
(. . .continued)
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tuberculosis mortality,25 tuberculosis 
treatment failure,26 and relapse after 
treatment completion.27,28 In a study in 
Brazil, it was found that – even after ad-
justing for confounders – smoking was 
associated with sputum culture positiv-
ity after 60 days of first-line tuberculosis 
treatment.23 Among patients with pul-
monary tuberculosis in India, smokers 
were found to have a threefold greater 
risk of recurrent tuberculosis than 
non-smokers.28 Current smokers with 
tuberculosis were more likely to default 
on their treatment than non-smokers in 
the Hong Kong Special Administrative 
Region (aOR: 3.00; 95% CI: 1.41–6.39)29 
and in Nigeria (odds ratio: 1.61; 95% 
CI: 1.31–1.98)30 In Morocco, one study 
found that smokers were twice as likely 
to fail tuberculosis treatment as non-
smokers26 – although the researchers did 
not control for important confounders 
such as previous tuberculosis treatment 
and use of a second-line treatment 
regimen.
Biological mechanisms related to 
smoking that impair host defences and 
increase the risk of M. tuberculosis infec-
tion probably contribute to the relatively 
poor results of tuberculosis treatment 
among smokers. For example, smoking 
may have an irreversible inhibitory effect 
on nitric oxide synthase – the enzyme 
needed by alveolar macrophages to form 
nitric oxide to inhibit the multiplication 
of M. tuberculosis.31,32 Cigarette smoking 
can increase the availability of iron in 
the lower respiratory tract33 and iron 
may bind with nitric oxide to generate 
toxic radicals34 that can interfere with 
alveolar macrophages.35 Smoking also 
probably reduces the ability of alveolar 
macrophages to mount an effective pul-
monary immune defence by altering the 
cells’ expression of pro-inflammatory 
cytokines.36
Our study had several limitations. 
First, our primary exposure variable 
– self-reported smoking status – was 
subject to potential misclassification. It 
is possible that our participants under-
reported their tobacco use. However, 
our questionnaires were administered 
by the research team and not by the 
patients’ health-care providers. This 
should have reduced the likelihood that 
patients underreported their tobacco 
use.37 Moreover, self-reported mea-
sures of tobacco use have been found 
to be reasonably accurate – with less 
than 1.5% of respondents claiming not 
to use tobacco when they are current 
users.38 If we misclassified some smok-
ers as never smokers, our estimate of 
the effect of smoking on tuberculosis 
outcomes would be an underestimate 
and our main findings would remain 
unchanged. Second, as there are prob-
ably patient characteristics associated 
with both smoking and poor tubercu-
losis treatment outcomes that we failed 
to include in our multivariable models, 
such models may have been affected by 
residual confounding. However, we did 
adjust for all of the key factors that have 
been established as important risks for 
a poor tuberculosis treatment outcome 
– e.g. a history of previous tuberculosis 
treatment, baseline sputum-smear score 
and the use of a second-line treatment 
regimen. Third, as our data came from 
patients with tuberculosis attending 
treatment facilities in Tbilisi, our find-
ings may not be nationally represen-
tative. However, the distributions of 
patient demographics, smear positivity 
and previous tuberculosis treatment 
history seen in our study are similar to 
those reported by WHO for Georgia.39
In conclusion, smoking is an inde-
pendent risk factor for poor tuberculosis 
treatment outcomes. Smoking cessation 
programmes need to be targeted at tu-
Table 4. Adjusted associations between smoking history and risk of poor tuberculosis 
treatment outcomes, Georgia, 2011–2012
Smoking history Adjusted risk ratio (95% CI)a
Model 1 – smoking status
Never smoker 1.00
Past smoker 1.24 (0.71–2.17)
Current smoker 1.70 (1.00–2.90)
Model 2 – smoking status
Never smoker 1.00
Past smoker 1.01 (0.51–1.99)
Ceased smoking in previous two months 1.44 (0.80–2.57)
Current smoker 1.69 (1.00–2.86)
Model 3 – smoking status
Never smoker 1.00
Past smoker 1.01 (0.50–2.04)
Current smokerb 1.67 (0.99–2.83)
Model 4 – smoking status
Never smoker 1.00
Past smoker 0.85 (0.39–1.88)
Current smokerc 1.64 (0.98–2.75)
Model 5 – smoking frequency
Never or past smoker 1.00
Less than daily 1.29 (0.52–3.19)
Daily 1.46 (1.05–2.04)
Model 6 – smokeless tobacco use
No 1.00
Yes 1.63 (0.52–5.15)
Model 7 – second-hand exposure to tobacco 
smoke in household
Never 1.00
Less than daily or daily 1.11 (0.86–1.44)
Model 8 – smoking status
Never or past smoker 1.00
Current smoker 1.45 (1.05–2.01)
CI: confidence interval.
a  Adjusted risk ratio for a poor treatment outcome – i.e. death or treatment default or failure – six months 
after the initiation of treatment. Derived from a multivariable logistic regression model that was adjusted 
for sex, age, income, prison history, alcohol use, previous tuberculosis treatment, baseline smear status 
and use of second-line treatment.
b  Including patients who ceased smoking before two months of enrolment.
c  Including patients who ceased smoking before four months of enrolment.
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摘要
吸烟和结核病治疗效果：在格鲁吉亚开展的前瞻性群组研究
目的 旨在评价格鲁吉亚第比利斯境内吸烟对结核病治
疗效果的影响。
方法 从 2011 年 5 月至 2013 年 11 月，我们在经实验
室确诊患有结核病的成人中开展了一项前瞻性群组研
究，并且通过改编自全球成人烟草调查的标准化问卷
收集了吸烟史资料。我们认为如果参与者违约、不进
行治疗或死亡，那么结核病治疗会有不良的效果。我
们采用多变量回归分析的方法评估了不良治疗效果的
风险。
结果 在参与调查的 591 名结核病患者中，其中 188 名 
(31.8%) 是既往吸烟者，271 名 (45.9%) 是目前吸烟者。
目前吸烟者中有 90 名 (33.2%)、从未吸烟者中有 24 名 
(18.2%) 曾在之前因结核病接受过治疗 (P < 0.01)。治疗
效果数据对 524 名参与者均为有效可用，其中 128 名 
(24.4%) 参与者的治疗效果不良，包括 243 名目前吸烟
者中的 80 名 (32.9%) 和 122 名从未吸烟者中的 21 名 
(17.2%)。与从未吸烟者相比，目前吸烟者产生不良治
疗效果的风险较高（调整过的相对风险，aRR ：1.70 ；
95% 置信区间，CI ：1.00–2.90）。那些在参与调查之
前已戒烟两个月以上的人并未增加该风险 (aRR:1.01 ；
95% CI ： 0.51–1.99)。
结论 格鲁吉亚境内结核病患者吸烟流行率很高，并且
吸烟增加了产生不良治疗效果的风险。
Résumé
Tabagisme et résultats des traitements antituberculeux : étude de cohorte prospective en Géorgie
Objectif Évaluer l’effet du tabagisme sur les résultats des traitements 
antituberculeux à Tbilissi, en Géorgie.
Méthodes Nous avons réalisé une étude de cohorte prospective chez 
des adultes atteints de tuberculose confirmée en laboratoire, de mai 
2011 à novembre 2013. Les antécédents de tabagisme ont été recueillis 
à l’aide d’un questionnaire standardisé, adapté de l’enquête mondiale 
sur le tabagisme des adultes. Nous avons considéré que les résultats 
du traitement antituberculeux étaient mauvais si les participants ne 
l’avaient pas respecté, n’avaient pas répondu au traitement ou étaient 
décédés. Nous avons utilisé des régressions multivariées pour estimer 
le risque de mauvais résultats thérapeutiques.
Résultats Sur les 591 patients atteints de tuberculose, 188 (31,8%) 
étaient d’anciens fumeurs et 271 (45,9%) fumaient encore. Quatre-
vingt-dix (33,2%) fumeurs actuels et 24 (18,2%) participants n’ayant 
jamais fumé avaient précédemment pris un traitement contre la 
tuberculose (P < 0,01). Les données sur les résultats des traitements 
étaient disponibles pour 524 des participants, sur lesquels 128 (24,4%) 
– dont 80 (32,9%) des 243 fumeurs actuels et 21 (17,2%) des 122 
personnes n’ayant jamais fumé – montraient de mauvais résultats 
thérapeutiques. Comparés aux personnes n’ayant jamais fumé, les 
berculosis patients – both by clinicians 
specializing in tuberculosis and by na-
tional tuberculosis control initiatives. 
The effectiveness of such programmes – 
in reducing smoking among tuberculo-
sis patients and improving tuberculosis 
treatment outcomes – also needs to be 
assessed. ■
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صخلم
ايجروج في ةيقابتسا ةيبارتأ ةسارد :لسلا جلاع لئاصحو غبتلا ينخدت
 جلاع  ةليصح  لىع  غبتلا  ينخدت  نع  جتانلا  يرثأتلا  مييقتل  ضرغلا
.ايجروج ،سييّلبت في لسلا ضرم
 نوناعي نيذلا ينغلابلا لىع ةيقابتسا ةيبارتأ ةسارد انيرجأ دقل ةقيرطلا
 لىإ 2011 ويام/رايأ ينب ام ةترفلا في اًيبرتمخ دكؤلما لسلا ضرم نم
 غبتلا  ينخدت  خيرات  عيمتج  مت  دقو  .2013  برمفون/نياثلا  نيشرت
 كلاهتسلا  يلماعلا  حسلما  نم  دمتعم  يرايعم  نايبتسا  مادختساب
 ةليصح هنع جتني  لسلا  جلاع نأ  اندجو دقل  .ينغلابلا  ىدل  غبتلا
 .اوفوت وأ ،مهجلاع لشف وأ ،ةلجاعلما نع نوكراشلما فلتخ اذإ ةئيس
 جتانلا  راطتخلاا  ريدقتل  تايرغتلما  ةددعتم  تافوتح  انمدختسا  دقل
.ةئيسلا جلاعلا ةليصح نع
 188  ناك  ،ينلجسلما  لسلا  ضىرم  نم  591  ينب  نم  جئاتنلا
 )45.9٪(  271  ناكو  ينقباس  يننخدم  ضىرلما  نم  )31.8٪(
 نم  )33.2٪(  ينعستل  قبس  دقل  .ينيلاح  يننخدم  ضىرلما  نم
 اونخدي لم نيذلا ينكراشلما نم )18.2٪( 24 و ،ينيلالحا يننخدلما
 ترفوتو  .)0.01  <  لماتحلاا(  لسلا  ضرم  نم  جلاعلا  ،اًدبأ
 128  مهنيب نم ،ينكراشلما نم 524 ددعل جلاعلا ةليصح تانايب
 80 كلذ في ماب ،ةئيس مبه ةصالخا جلاعلا ةليصح تناك )24.4٪(
 نم  )17.2٪(  21و  ينيلالحا  يننخدلما  نم  243  نم  )32.9٪(
 لم نيذلا كئلوأ عم ةنراقم .اًدبأ اونخدي لم نيذلا دارفلأا نم 122
 ثودلح ينيلالحا يننخدلما لىع دئاز راطتخا كانه ناك ،اًدبأ اونخدي
 ؛aRR: 1.70  ،ححصلما  يبسنلا  راطتخلاا(  ةئيس  جلاع  ةليصح
 نيذلا  كئلوأ.)2.90  لىإ  1.00  :95٪  اهرادقم  ةيحجرأ  ةبسنب
 نكي لم ،ليجستلا لبق نيرهش نم رثكأ ةدلم ينخدتلا نع اوعلقأ دق
 ةيحجرأ  ةبسنب  ؛aRR 1.01:(  دئازلا  راطتخلاا  كلذ  لثم  ميهدل
.)1.99 لىإ 0.50 :95٪ اهرادقم
 نوناعي  نيذلا  ضىرلما  ينب  ينخدتلل  عفترم  راشتنا  كانه  جاتنتسلاا
 ةليصح راطتخا نم ينخدتلا  ديزيو ،ايجروج في لسلا ضرم نم
 .ةئيسلا جلاعلا
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fumeurs actuels présentaient un risque accru de mauvais résultats 
thérapeutiques (risque relatif ajusté, RRa : 1,70 ; intervalle de confiance 
de 95%, IC : 1,00-2,90). Les personnes qui avaient arrêté de fumer 
plus de deux mois avant leur inclusion à l’étude ne présentaient pas 
une telle augmentation du risque (RRa : 1,01 ; IC de 95% : 0,51-1,99).
Conclusion Il existe une forte prévalence de tabagisme chez les patients 
atteints de tuberculose en Géorgie et le tabagisme augmente le risque 
de mauvais résultats thérapeutiques.
Резюме
Табакокурение и исходы лечения туберкулеза: проспективное когортное исследование в Грузии
Цель Оценка воздействия табакокурения на исход лечения 
туберкулеза в Тбилиси, Грузия.
Методы В период с мая 2011 г. по ноябрь 2013 г. было 
проведено проспективное когортное исследование взрослого 
населения с диагнозом туберкулеза, подтвержденным данными 
лабораторных анализов. С помощью стандартизированной 
анкеты, разработанной на основе Глобального опроса взрослого 
населения о потреблении табака (GATS), была собрана история 
табакокурения участников. Исход лечения туберкулеза 
рассматривался нами как плохой, если участник исследования 
не доводил лечение до конца, лечение не было эффективным или 
участник исследования умирал. Для оценки риска плохого исхода 
лечения использовались многопараметрические регрессии.
Результаты В исследовании принял участие 591 пациент с 
туберкулезом, из которых 188 человек (31,8 %) ранее были 
курильщиками, а 271 человек (45,9 %) курил на момент начала 
исследования. Девяносто человек (33,2 %) из числа активных 
курильщиков и 24 человека (18,2 %) из числа тех участников, 
которые никогда не курили, ранее получали лечение от 
туберкулеза (P < 0,01). Данные по исходу лечения были доступны 
для 524 участников, из которых исход лечения был плохим у 128 
человек (24,4 %). В это число входили 80 человек (32,9 %) из числа 
243 активных курильщиков и 21 (17,2 %) из тех 122, кто никогда 
не курил. По сравнению с теми, кто никогда не курил, у активных 
курильщиков был выявлен повышенный риск плохого исхода 
лечения (скорректированный относительный риск, ОР: 1,70; 
95 % доверительный интервал, ДИ: 1,00–2,90). У тех, кто бросил 
курить более чем за два месяца до вступления в исследование, 
риск был не таким высоким (скорректированный ОР: 1,01; 95 % 
ДИ: 0,51–1,99).
Вывод У пациентов с туберкулезом в Грузии широко 
распространено курение, и курение увеличивает риск плохого 
исхода лечения.
Resumen
El consumo de tabaco y los resultados del tratamiento de la tuberculosis: un estudio de cohortes prospectivo en Georgia
Objetivo Evaluar los efectos del consumo de tabaco en los resultados 
del tratamiento de la tuberculosis en Tbilisi, Georgia.
Métodos Se llevó a cabo un estudio de cohortes prospectivo en adultos 
con tuberculosis confirmada mediante pruebas de laboratorio de 
mayo de 2011 a noviembre de 2013. Se recopiló información sobre el 
consumo de tabaco mediante un cuestionario normalizado adaptado a 
partir de la Encuesta Mundial sobre el Tabaco y los Adultos. Se consideró 
que los resultados de la terapia antituberculosa eran deficientes si los 
participantes incumplían el tratamiento, no lo realizaban o morían. Se 
utilizaron regresiones multivariables para estimar el riesgo de obtener 
unos resultados deficientes del tratamiento.
Resultados De los 591 pacientes con tuberculosis inscritos, 188 
(31,8%) eran antiguos fumadores y 271 (45,9%) eran fumadores 
actuales. Noventa (33,2%) de los fumadores actuales y 24 (18,2%) 
de los participantes que no habían fumado nunca habían recibido 
tratamiento para la tuberculosis anteriormente (P < 0,01). Los datos 
sobre los resultados del tratamiento estuvieron disponibles para 524 
de los participantes, de los cuales 128 (24,4%) (incluyendo los 80 
(32,9%) de los 243 fumadores y 21 (17,2%) de las 122 personas que 
nunca habían fumado) obtuvieron unos resultados deficientes del 
tratamiento. En comparación con las personas que no habían fumado 
nunca, los fumadores actuales tenían un riesgo superior de obtener 
unos resultados deficientes del tratamiento (riesgo relativo ajustado, RRa: 
1,70; intervalo de confianza, IC, del 95%: 1,00–2,90). Aquellas personas 
que habían dejado de fumar más de dos meses antes de la inscripción 
no experimentaban un aumento del riesgo tan elevado (RRa: 1,01 (IC 
del 95%: 0,51–1,99).
Conclusión Existe una elevada prevalencia de consumo de tabaco 
entre los pacientes con tuberculosis en Georgia y el consumo de 
tabaco aumenta el riesgo de obtener unos resultados deficientes del 
tratamiento.
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